Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06647277 · ClinicalTrials.gov registry record · Phase 1
Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease
A Phase 1 study, sponsored by ProgenaBiome.
- Not yet
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06647277 is a Phase 1 study that has not yet begun recruiting, run by ProgenaBiome. The registered enrollment target is 10 participants.
The verdict
NCT06647277, a Phase 1 study, has not yet begun recruiting, sponsored by ProgenaBiome.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.
Interventions
- COMBINATION_PRODUCT Fecal Microbiota Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06647277
The ClinicalTrials.gov registry entry for NCT06647277 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ProgenaBiome, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fecal Microbiota Transplant is the first listed.
NCT06647277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06647277 about?
NCT06647277 is a clinical study titled "Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease". FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.
What is the current status of trial NCT06647277?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2026-07. Estimated completion is 2027-12.
What interventions are being tested in trial NCT06647277?
The interventions under investigation include: Fecal Microbiota Transplant (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06647277?
This trial is sponsored by ProgenaBiome, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.